Abstract
Introduction
Serum eye drops (SED) are an important treatment for patients with chronic and severe ocular surface disease (OSD). Despite a long history of use, there is a paucity of information on patient-reported outcomes, particularly comparing autologous SED (Auto-SED) and allogeneic SED (Allo-SED). National Health Service Blood and Transplant is the national provider of SED service for patients in the UK.
Purpose
To evaluate and compare patient-reported outcome measures (PROMs) in patients receiving Auto-SED and Allo-SED for severe OSD.
Materials and methods
PROMs were retrospectively collected from all new patients commencing treatment with Auto-SED and Allo-SED between January 2017 and September 2018, using the Ocular Surface Disease Index (OSDI) 12-item questionnaire. A linear mixed model was used to evaluate the change in OSDI scores between baseline and follow-up.
Results
During the study period, 279 patients who received either Auto-SED (n = 71) or Allo-SED (n = 208) were included in the analysis. Baseline and follow-up OSDI scores were available for 161 of these (49 Auto-SED and 112 Allo-SED). There was a significant reduction in mean OSDI score for both Auto-SED (59.06–24.63, p < 0.001) and Allo-SED (64.21–34.37, p < 0.001). There was no significant difference between Auto-SED and Allo-SED patients in terms of the reduction in the OSDI score (p = 0.27).
Conclusion
Both Auto-SED and Allo-SED were associated with improvements in the quality of life of patients with chronic and severe OSD. Auto-SED and Allo-SED were equally effective in relieving the symptoms of OSD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EC, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438–510.
Buchholz P, Steeds CS, Stern LS, Wiederkehr DP, Doyle JJ, Katz LM, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006;4:155–61.
Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984;27:459–61.
Rauz S, Koay SY, Foot B, Kaye SB, Figueiredo F, Burdon MA, et al. The Royal College of Ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: executive summary. Eye. 2018;32:44–8.
Chiang CC, Lin JM, Chen WL, Tsai YY. Allogeneic serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Cornea. 2007;26:861–3.
Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond). 2009;23:290–3.
Hung Y, Elder MJ, Rawstron JA, Badami KG. A retrospective crossover study of autologous and allogeneic serum eye drops for the management of ocular surface disease. Transfus Med. 2019;29:69–71.
Harritshøj LH, Nielsen C, Ullum H, Hansen MB, Julian HO. Ready-made allogeneic ABO-specific serum eye drops: production from regular male blood donors, clinical routine, safety and efficacy. Acta Ophthalmol. 2014;92:783–6.
Pan Q, Angelina A, Marrone M, Stark WJ, Akpek EK. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;2:CD009327.
Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004;88:647–52.
Walt JG, Rowe MM, Stern KL. Evaluating the functional impact of dry eye: the Ocular Surface Disease Index. Drug Inf J. 1997;31:1436.
Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000;118:615–21.
Celebi AR, Ulusoy C, Mirza GE. The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study. Graefes Arch Clin Exp Ophthalmol. 2014;252:619–26.
Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012;37:684–8.
Campos E, Versura P, Buzzi M, Fontana L, Giannaccare G, Pellegrini M, et al. Blood derived treatment from two allogeneic sources for severe dry eye associated to keratopathy: a multicentre randomised cross over clinical trial. Br J Ophthalmol. 2020;104:1142–7.
Acknowledgements
The authors would like to thank Dr. J. B. Mueller, Dr. L. Gaum, J. Leyland and J. Dobie for their help with data collection for this study, D. Stinson for secretarial support and Dr. E. Allen, Principal Statistician, Statistics and Clinical Studies NHS Blood and Transplant for her help with the statistical analyses.
Author information
Authors and Affiliations
Contributions
RJL, AC, SR, SK and FCF were responsible for designing the study protocol. RJL was the primary author of the manuscript, with input provided by AC, SR, SK and FCF. CMcW developed the statistical analysis protocol and carried out all analyses.
Corresponding author
Ethics declarations
Conflict of interest
RJL, AC and CMcW are employees of NHS Blood and Transplant, accredited suppliers of the serum eye drops service in the UK.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Lomas, R.J., Chandrasekar, A., Macdonald-Wallis, C. et al. Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK. Eye 35, 3425–3432 (2021). https://doi.org/10.1038/s41433-021-01560-8
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-021-01560-8
